How we work with the pharmaceutical industry
Myeloma UK is committed to working in partnership with all stakeholders with an interest in myeloma and who share our goals to improve the lives of people affected by myeloma.
Working with the pharmaceutical industry can include activities such as making sure that the patient voice counts in designing and delivering trials or advocating for access to effective new treatments. Work like this can change lives – it is key to achieving our mission of helping people to live longer and better lives with myeloma and it can only be done by working together.
Why working together is essential
Working with pharmaceutical companies allows us to:
- Accelerate Research: Partnerships can help fund ground-breaking research projects that bring us closer to finding a cure for myeloma.
- Improve Treatments: By working together, we support the development and availability of new and effective treatments for patients.
- Enhance Patient Care: Through joint initiatives, we provide crucial resources and support to improve the quality of life for those living with myeloma.
Our Independence
Whilst we value our relationships with pharmaceutical companies, we always maintain our integrity and independence and ensure that our activities are driven solely by the best interests of people affected by myeloma.
Myeloma UK will not endorse or promote individual products or services. This is made clear to any pharmaceutical company seeking our advice or assistance at the first time of contact.
We do not accept funding from pharmaceutical companies for our advocacy work in supporting the approval of new treatments or for our specific access policy work. We also don’t accept funding for work from companies seeking NHS approval for medical technologies, diagnostics, or other similar products where that work would be about promoting those technologies to improve the chance of them being funded by the NHS.
We are also transparent about the funding we receive from pharmaceutical companies.
Pharmaceutical Industry Funding
Receiving grant or other funding from pharmaceutical companies can accelerate or increase the impact of our work to help people with myeloma live longer and better lives.
All funds received from the pharmaceutical industry are received and dispersed within clear ethical guidelines as laid down by the ‘ABPI Code of Practice, Clause 27 – Relationships with Patient Organisations’
Myeloma UK receives funding from a wide range of pharmaceutical companies. We will not accept more than 15% of our annual income from the pharmaceutical industry.
Why is this important?
The pharmaceutical, life sciences, and diagnostics industries deliver medical and scientific innovation that is vital to improving outcomes and experience for people living with myeloma.
Whilst we welcome funding from industry which helps us to put people living with myeloma at the centre of innovation, we have a duty to do all that we can to ensure that work we do is patient-centred and driven only by what people living with myeloma tell us is important to them. We believe that accepting no more than 15% of funding from industry is a proportionate amount which enables us to accept grants and other income at a level which reflects our expertise and can deliver tangible outcomes, whilst protecting our independence and integrity.
Our current partnerships
In 2025, we received £219,443 of funding from pharmaceutical and industry sources.
This represents 3.78% of our annual income.
These figures report cash received in 2025 and may differ slightly from figures reported in our 2025 Annual Report, which are reported on funds received basis.
We would like to thank the following companies for their support:
| Company | Project Description and Amount |
|---|---|
| AKT Health Communications | £720 for preparation and participation in an EU HTA Regulation Takeda EUCAN educational webinar |
| Adaptive Biotech | £500 for Consultancy services for BSH symposium |
| The Binding Site | £50,000 core activities funding |
| Bristol-Myers Squibb Pharmaceuticals Ltd | £10,000 core activities funding |
| Gilead Sciences | £15,000 for Myeloma UK Health Inequalities Programme |
| GlaxoSmithKline UK Limited | £20,000 in April 2025 for the purpose of supporting the cost of the publication and updating information guides activities £672 for consultancy £3,182 for eight participants on the Jurassic Coast Hike £810 for attendance at Life Changers Conversations Event 23rd June 2025 |
| Johnson & Johnson | £8,000 funding for core activities £975 for attendance at J&J Hematology Summit 28 March 2025 presentation on the ‘Healthcare System & Societal Costs of Multiple Myeloma’ £216 Preparation and attendance at CAR-T Patient Journey £126 for attendance at a J&J nurse study day £465.64 for attendance at the Oncology summit £20,787 for thirteen participants in London Paris 2026 Bike Ride £850 in match funding 2024 London Paris Bike Ride £798 for two participants in the Jurassic Coast Hike 2025 |
| Kyowa Kirin Ltd | £5,000 for Myeloma UK Health Inequalities Programme |
| Pfizer Limited | £5,994 for Pfizer research project and £1,000 for consultancy £347.13 covering expenses covering work on the Qualitative Research Project on Patient and Caregiver needs in Multiple Myeloma project |
| Sanofi Specialty Care | £20,000 for the myeloma nurse learning programme £36,990 for nine participants and sponsorship of the London Paris Bike Ride 2026 £7,000 for five participants and sponsorship for the Jurassic Coast Hike 2025 |
| Takeda UK Ltd | £10,000 core activities funding |
We extend our thanks to our pharmaceutical and industry funders for their support of our ongoing work.
Contact
If you have any questions or would like to find out more about our work with pharmaceutical companies, please drop us an email at partnerships@myeloma.org.uk.
Stay in touch
We’d love to stay in touch. Join our mailing list to receive updates from Myeloma UK including our monthly newsletter and updates about our services, research, campaigns and other ways you can get involved.
